Table 1.
Gene | Biological role/behaviour | PDAC implications | Ref. |
OCT4 | Overexpressed in 69% of PDAC. Pro-oncogenic role | Correlation with N1/M1 status and indicative of worse prognosis | Polvani et al[47], 2013 |
Overexpressed in 48.8% of PDAC. Induces cell proliferation, migration and invasion | Contribution to metastasis and drug resistance | Lu et al[50], 2013 | |
Overexpressed in human cell lines | Multidrug resistance and metastasis | Wang et al[52], 2013 | |
Induction of tumorigenic capacity | Chemo-resistance | Wang et al[53], 2013 | |
Overexpressed in 79.2% metaplastic ducts | Early carcinogenesis and worse prognosis | Wen et al[49], 2010 | |
SOX2 | Overexpressed in poorly differentiated human tumors | Correlation to aggressiveness | Sanada et al[54], 2006 |
Ectopic expression in 19.3% of PDAC. Promotes cancer cell proliferation/dedifferentiation | Rapid tumor progression and poor differentiation | Herreros-Villanueva et al[38], 2013 | |
Induction of tumorigenic capacity | Chemo-resistance | Wang et al[53], 2013 | |
NANOG | Overexpressed in 53.5% of PDAC. Induces proliferation, migration and invasion | Associated with eraly stage carcinogenesis and worse overall survival | Lu et al[50], 2013 |
Overexpressed in cells capable of initiating spheres | Resistance to 5-FU treatment | Lonardo et al[68], 2013 | |
Overexpressed in pancreatic tumors | Contribution to carcinogenesis and correlates to worse prognosis | Wen et al[49], 2010 |
PDAC: Pancreatic ductal adenocarcinoma.